Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOSTAVAX safety and tolerability trial in adults aged 60 years or older
NL-OMON31293Phase 4Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in herpes zoster (HZ) comparing ZOSTAVAX with Placebo (2 arms). Primary endpoint: Proportion of subjects with serious clinical adverse experiences through Day 42 postvaccination. Planned start Sep 2007; status: withdrawn.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NL-OMON31293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31293.